These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28104306)

  • 21. Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial.
    Wijns W; Steg PG; Mauri L; Kurowski V; Parikh K; Gao R; Bode C; Greenwood JP; Lipsic E; Alamgir F; Rademaker-Havinga T; Boersma E; Radke P; van Leeuwen F; Camenzind E;
    Eur Heart J; 2014 Oct; 35(40):2812-20. PubMed ID: 25106761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
    Camenzind E; Boersma E; Wijns W; Mauri L; Rademaker-Havinga T; Ordoubadi FF; Suttorp MJ; Al Kurdi M; Steg PG;
    Eur Heart J; 2014 Aug; 35(29):1932-48. PubMed ID: 24627416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy.
    Urban P; Abizaid A; Chevalier B; Greene S; Meredith I; Morice MC; Pocock S
    Am Heart J; 2013 May; 165(5):704-9. PubMed ID: 23622906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).
    Campo G; Tebaldi M; Vranckx P; Biscaglia S; Tumscitz C; Ferrari R; Valgimigli M
    J Am Coll Cardiol; 2014 Feb; 63(6):506-12. PubMed ID: 24161321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial.
    Verdoia M; Suryapranata H; Damen S; Camaro C; Benit E; Barbieri L; Rasoul S; Liew HB; Polad J; Ahmad WAW; Zambahari R; Lalmand J; van der Schaaf RJ; Koh TH; Timmermans P; Dilling-Boer D; Veenstra LF; Van't Hof AWJ; Lee SWL; Roolvink V; Ligtenberg E; Postma S; Kolkman EJJ; Brouwer MA; Kedhi E; De Luca G
    J Thromb Thrombolysis; 2021 Oct; 52(3):797-807. PubMed ID: 33847862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents.
    El-Hayek G; Messerli F; Bangalore S; Hong MK; Herzog E; Benjo A; Tamis-Holland JE
    Am J Cardiol; 2014 Jul; 114(2):236-42. PubMed ID: 24856318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis.
    Palmerini T; Sangiorgi D; Valgimigli M; Biondi-Zoccai G; Feres F; Abizaid A; Costa RA; Hong MK; Kim BK; Jang Y; Kim HS; Park KW; Mariani A; Della Riva D; Genereux P; Leon MB; Bhatt DL; Bendetto U; Rapezzi C; Stone GW
    J Am Coll Cardiol; 2015 Mar; 65(11):1092-102. PubMed ID: 25790880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical impact of dual antiplatelet therapy use in patients following everolimus-eluting stent implantation: insights from the SEEDS study.
    Zhang YJ; Zhao YL; Xu B; Han YL; Li B; Liu Q; Su X; Pang S; Lu SZ; Guo XF; Yang YJ
    Chin Med J (Engl); 2015 Mar; 128(6):714-20. PubMed ID: 25758261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nine-month clinical outcomes in patients with diabetes treated with polymer-free sirolimus-eluting stents and 6‑month vs. 12‑month dual-antiplatelet therapy (DAPT).
    Krackhardt F; Waliszewski M; Rischner J; Piot C; Pansieri M; Ruiz-Poveda FL; Boxberger M; Noutsias M; Ríos XF; Kherad B
    Herz; 2019 Aug; 44(5):433-439. PubMed ID: 29356832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes following implantation of the Biolimus A9-eluting BioMatrix coronary stent: Primary analysis of the e-BioMatrix registry.
    Urban P; Valdés M; Menown I; Eberli F; Alhaddad I; Hildick-Smith D; Iosseliani D; Roffi M; Oldroyd K; Kalloudi E; Eerdmans P; Berland J; Kleber FX;
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1151-60. PubMed ID: 25683225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.
    Mehran R; Baber U; Steg PG; Ariti C; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Berger PB; Iakovou I; Dangas G; Waksman R; Antoniucci D; Sartori S; Krucoff MW; Hermiller JB; Shawl F; Gibson CM; Chieffo A; Alu M; Moliterno DJ; Colombo A; Pocock S
    Lancet; 2013 Nov; 382(9906):1714-22. PubMed ID: 24004642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
    Valgimigli M; Patialiakas A; Thury A; McFadden E; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Airoldi F; Ferlini M; Liistro F; Dellavalle A; Vranckx P; Briguori C;
    J Am Coll Cardiol; 2015 Mar; 65(8):805-815. PubMed ID: 25720624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of six versus 12 months of dual antiplatelet therapy in patients with drug-eluting stent implantation after risk stratification with the residual SYNTAX score: Results from a secondary analysis of the I-LOVE-IT 2 trial.
    Qiu M; Li Y; Li J; Xu K; Jing Q; Dong S; Jin Z; Zhao P; Xu B; Han Y
    Catheter Cardiovasc Interv; 2017 Mar; 89(S1):565-573. PubMed ID: 28211603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
    Lee SY; Hong MK; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Kim HS; Valgimigli M; Palmerini T; Stone GW
    Clin Res Cardiol; 2017 Mar; 106(3):165-173. PubMed ID: 27631821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions.
    Mauri L; Kereiakes DJ; Normand SL; Wiviott SD; Cohen DJ; Holmes DR; Bangalore S; Cutlip DE; Pencina M; Massaro JM
    Am Heart J; 2010 Dec; 160(6):1035-41, 1041.e1. PubMed ID: 21146655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial.
    Han Y; Xu B; Xu K; Guan C; Jing Q; Zheng Q; Li X; Zhao X; Wang H; Zhao X; Li X; Yu P; Zang H; Wang Z; Cao X; Zhang J; Pang W; Li J; Yang Y; Dangas GD
    Circ Cardiovasc Interv; 2016 Feb; 9(2):e003145. PubMed ID: 26858080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal duration of dual antiplatelet therapy following treatment with the endeavor zotarolimus-eluting stent in real-world Japanese patients with coronary artery disease (OPERA): study design and rationale.
    Nakamura M; Nanto S; Hirayama A; Takayama T; Nishikawa M; Kimura K; Morita S; Aizawa T; Asano R; Matsumaru Y; Hamada C; Isshiki T;
    Catheter Cardiovasc Interv; 2014 Sep; 84(3):368-74. PubMed ID: 24382824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial".
    Kedhi E; Fabris E; van der Ent M; Kennedy MW; Buszman P; von Birgelen C; Cook S; Wedel H; Zijlstra F
    Am Heart J; 2017 Jun; 188():11-17. PubMed ID: 28577666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease.
    Lee HJ; Yu CW; Hwang HK; Choi RK; Park JS; Li H; Ro YM
    Coron Artery Dis; 2013 Nov; 24(7):542-8. PubMed ID: 23994880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.